Global Vitiligo Market Forecast Report by Diseases Type (Segmental, Non-Segmental) Treatment Type (Topical Treatments, Light Therapy, Surgical Procedures, Others) End User (Hospitals, Ambulatory Clinics, Others) Countries and Company Analysis, 2024-2032

Growth Factors in the Vitiligo Industry

The Increase in Healthcare expenses

The market for vitiligo is anticipated to develop as a result of rising healthcare costs. An expense that encompasses all costs related to providing family planning, emergency assistance, nutrition, and health services is referred to as a healthcare expenditure. Raising the amount spent on healthcare will help treat vitiligo patients more effectively overall. Furthermore, by combining primary care services with public health, efficient primary healthcare will advance population health. For example, in March 2022, the US Department of Health and Human Services' Centers for Medicare & Medicaid Services published the 2021–2030 National Health Expenditure (NHE) report, which predicted that national health spending would increase by 5.1% annually on average between 2021 and 2030, reaching roughly $6.8 trillion by that time. In addition, it is anticipated that between 2021 and 2030, Medicaid spending will increase at a 5.6% annual pace and Medicare spending will increase at a 7.2% annual rate.

Infrastructure spending in the healthcare sector is rising.

The increasing cost of healthcare is a major factor impacting the vitiligo market growth rate as well, as it contributes to the infrastructure's improvement. Additionally, by boosting funding, a number of government groups hope to strengthen the healthcare infrastructure, which would further alter the dynamics of the market.

Moreover, growing governmental and private sector campaigns to raise awareness would increase the market for vitiligo. In addition, the market for vitiligo will grow as a result of people's evolving lifestyles and increased disposable money. The market's growth rate will be accelerated by the rising acceptance of cosmetic surgery as well as other dermatology procedures and the expanding significance of aesthetic appeal.

North America Vitiligo Market Overview:

The Vitiligo market has been controlled by North America. The aforementioned expansion is ascribed to the prevalence of adult vitiligo in this region, heightened consciousness, and the presence of several industry participants. Furthermore, survey data revealed that between 0.76% and 1.11%, or 1.9 million and 2.8 million cases, were involved. The region is further supported by the existence of reimbursement activities. For example, the US-based Global Vitiligo Foundation covers the cost of required therapy. The program's main goal is to improve the quality of life for vitiligo sufferers through research, counseling, professional care, and community support. For the course of the projection period, there will be a sizable patient population and a substantial number of clinical studies.

Vitiligo Market Company Overview

Some of the industry leaders seen in the Global Vitiligo Market Includes Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals Ltd, Astellas pharma inc, Baxter International Inc., Pfizer, Dr. Reddy’s Laboratories Ltd.

Vitiligo Market News

In October 2023, Afamelanotide, or SCENESSE (16 mg), was given to the first patient with vitiligo in CUV105, a Phase III study sponsored by CLINUVEL. 200 vitiligo patients with darker skin types (Fitzpatrick Types IV–VI) will be enrolled in this experiment in order to compare the effectiveness of SCENESSE with narrowband UVB (NB-UVB) light therapy to NB-UVB alone.

In October 2023, according to AbbVie, the Phase 2b research of upadacitinib (RINVOQ) in patients with non-segmental vitiligo achieved the primary objective of comparing the 11 mg and 22 mg dosages to placebo at week 24 in terms of the percent change from base in the Facial Vitiligo Area Scoring Index (F-VASI). The percentage drop in F-VASI from baseline at week 52 for all upadacitinib dosages was higher than that at week 24. Beyond the established safety profile of upadacitinib, no additional safety signals were found. AbbVie is advancing its upadacitinib trial program for vitiligo to Phase 3 in light of these findings.

In June 2023, According to AVITA Medical, Inc., the FDA in the US has accepted the company's request for premarket approval (PMA) of its RECELL System for the treatment of vitiligo. RECELL, a one-time therapy at the point of care, is the first FDA-approved therapeutic device for repigmentation of stable depigmented vitiligo lesions. With the use of technology, a physician can safely and effectively treat vitiligo by preparing and transferring autologous skin cells from pigmented skin to stable depigmented patches.

In May 2023, the safety and effectiveness of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in treating adult patients with severe nonsegmental vitiligo were evaluated in a Phase 2b clinical trial, which was just released by Incyte. Povorcitinib treatment improved the overall repigmentation of the body and face in patients, and the experimental medication was well tolerated.

Disease Type – Market breakup in 2 viewpoints:

1. Segmental
2. Non-Segmental

Treatment Type – Market breakup in 4 viewpoints:

1. Topical Treatments
2. Light Therapy
3. Surgical Procedures
4. Others

End User – Market breakup in 3 viewpoints:

1. Hospitals
2. Ambulatory Clinics
3. Others

Country – Market breakup in 18 viewpoints:

• United States
• Canada
• Mexico
• Germany
• United Kingdom
• France
• Italy
• Spain
• Japan
• China
• Australia
• India
• Brazil
• Saudi Arabia
• Argentina
• United Arab Emirates
• South Africa
• Rest of the World

All the Key players have been covered from 5 Viewpoints:

1. Overviews
2. Key Person
3. Recent Developments & Strategies
4. Product Portfolio & Product Launch in Last 1 Year
5. Revenue

Company Analysis:

1. Incyte Corporation
2. Bristol-Myers Squibb
3. Clinuvel Pharmaceuticals Ltd
4. Astellas pharma inc
5. Baxter International Inc.
6. Pfizer
7. Reddy’s Laboratories Ltd

Report Details: